Although the potential benefits of combination therapy could not be fully assessed due to the small sample size of evaluable patients with ENKTL, investigating PD1 inhibitor combination therapy remains a crucial avenue for future research.The prognosis of PTCL-NOS and AITL is almost the worst among the subtypes. This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.